Recent Updates
Recently added Catalysts
ABEO Positive Sentiment

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Key Takeaway: Abeona Therapeutics announced its participation in two upcoming investor conferences in November 2026. The Stifel 2026 Healthcare Conference will feature a fireside chat on November 11, while the Jefferies Global Healthcare Conference will include a presentation on November 18. Live webcasts of these events will be accessible on their website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in notable investor conferences
  • Management team engagement with investors
  • Live webcasts available for broader access

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+64%
120-day peak, hindsight
Typical move
30.1%
average across 3 past catalysts
Cash runway
~49 mo
Low dilution risk
Lead asset
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Phase 2 · Epidermolysis Bullosa Dystrophica

Full Press Release Details

CLEVELAND, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2026:
• Stifel 2026 Healthcare Conference: Fireside chat on Wednesday November 11, 2026, at 8:40 AM Eastern Time (ET) and investor meetings.
• Jefferies Global Healthcare Conference: Presentation on Wednesday, November 18, 2026, at 10:30 AM Greenwich Mean Time (GMT) and investor meetings.
Live webcasts of the fireside chat and Company presentation can be accessed on the Investors section of the Abeona website under “Events” at https://investors.abeonatherapeutics.com/events, where replays of available events will also be accessible for a limited time.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company building a portfolio of therapies for rare and serious diseases with multiple opportunities for value creation. The Company’s portfolio includes ZEVASKYN® (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa; ABO-801, a Phase 3-ready product candidate for eosinophilic esophagitis; and ABO-701 (PSMA-SIR-T™), an investigational engineered T-cell therapy targeting PSMA. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.

Frequently Asked Questions

What conferences will Abeona Therapeutics attend?

Abeona Therapeutics will attend the Stifel 2026 and Jefferies Global Healthcare conferences.

When is the Stifel 2026 Healthcare Conference?

The Stifel 2026 Healthcare Conference is on November 11, 2026.

What will Abeona present at the Jefferies conference?

Abeona will present at the Jefferies Global Healthcare Conference on November 18, 2026.

How can I access the conference webcasts?

Live webcasts can be accessed on Abeona's website under the 'Events' section.

Last updated: Nov 10, 2026